ASCO 2024: Highlights and analysis

Share :
Published: 4 Jun 2024
Views: 1636
Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

Associate Professor Bishal Gyawali talks to ecancer reporter Saira Ahmed about several presentations from ASCO 2024; on topics such as patient-centric trials, lung cancer, melanoma, GI cancers and breast cancer.

The presentations referred to are:

Commentary on ASCO 2024's theme
Patient-centric trials at ASCO 2024
Osimertinib after definitive chemoradiotherapy (CRT) in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study
ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)
Lorlatinib vs crizotinib in treatment-naive patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Sacituzumab govitecan vs docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial
Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial))
Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET)
Trastuzumab deruxtecan vs physician's choice of chemotherapy in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)
First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC)